PL3404043T3 - Przeciwciało przeciwko cdh3 o dużej zdolności do internalizacji - Google Patents
Przeciwciało przeciwko cdh3 o dużej zdolności do internalizacjiInfo
- Publication number
- PL3404043T3 PL3404043T3 PL18182161.2T PL18182161T PL3404043T3 PL 3404043 T3 PL3404043 T3 PL 3404043T3 PL 18182161 T PL18182161 T PL 18182161T PL 3404043 T3 PL3404043 T3 PL 3404043T3
- Authority
- PL
- Poland
- Prior art keywords
- cdh3 antibody
- internalization capacity
- high internalization
- capacity
- cdh3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010243708 | 2010-10-29 | ||
| JP2011150812 | 2011-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3404043T3 true PL3404043T3 (pl) | 2023-01-02 |
Family
ID=45994030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11836461T PL2634194T3 (pl) | 2010-10-29 | 2011-10-28 | Przeciwciało przeciwko cdh3 o dużej zdolności do internalizacji |
| PL18182161.2T PL3404043T3 (pl) | 2010-10-29 | 2011-10-28 | Przeciwciało przeciwko cdh3 o dużej zdolności do internalizacji |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11836461T PL2634194T3 (pl) | 2010-10-29 | 2011-10-28 | Przeciwciało przeciwko cdh3 o dużej zdolności do internalizacji |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9328160B2 (pl) |
| EP (3) | EP3404043B1 (pl) |
| JP (2) | JP6006640B2 (pl) |
| CY (1) | CY1121061T1 (pl) |
| DK (2) | DK3404043T3 (pl) |
| ES (2) | ES2931477T3 (pl) |
| HR (1) | HRP20181438T1 (pl) |
| HU (1) | HUE039375T2 (pl) |
| LT (1) | LT2634194T (pl) |
| PL (2) | PL2634194T3 (pl) |
| PT (1) | PT2634194T (pl) |
| RS (1) | RS57646B1 (pl) |
| SI (1) | SI2634194T1 (pl) |
| WO (1) | WO2012057328A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130136689A1 (en) * | 2007-06-05 | 2013-05-30 | Christian Rohlff | Proteins |
| US20130058947A1 (en) * | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
| CA2869704A1 (en) | 2012-04-04 | 2013-10-10 | Perseus Proteomics Inc. | Drug conjugate comprising anti-cdh3 (pcadherin) antibody |
| HK1215959A1 (en) * | 2013-02-15 | 2016-09-30 | Perseus Proteomics Inc. | Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same |
| US10214584B2 (en) | 2014-01-15 | 2019-02-26 | Order-Made Medical Research Inc. | Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody |
| WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| TW201625692A (zh) * | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| JP2023509760A (ja) * | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| BR112022013601A2 (pt) * | 2020-01-10 | 2022-09-13 | Kling Biotherapeutics B V | Anticorpos específicos de caderina epitelial |
| US20240000960A1 (en) * | 2020-11-16 | 2024-01-04 | The Cleveland Clinic Foundation | Anti-cd6 antibody conjugates for treating t-cell mediated disorders and t-cell lymphoma/leukemia |
| IL317689A (en) | 2022-07-15 | 2025-02-01 | Boehringer Ingelheim Int | Binding molecules for cancer treatment |
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| WO2025237234A1 (en) * | 2024-05-13 | 2025-11-20 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-cdh3 antibodies and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| CA2345160A1 (en) | 2001-04-25 | 2002-10-25 | Roy Fenwick | Multifunctional flower pot |
| US20030194406A1 (en) * | 2001-05-31 | 2003-10-16 | Chiron Corporation | P-cadherin as a target for anti-cancer therapy |
| US20050037445A1 (en) | 2001-06-25 | 2005-02-17 | Poulsen Hans Skovgaard | Oncology drug innovation |
| JP2006089471A (ja) * | 2004-08-26 | 2006-04-06 | National Institute Of Advanced Industrial & Technology | 癌の治療における抗モータリン２抗体と機能性核酸の使用 |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US8603483B2 (en) * | 2004-12-09 | 2013-12-10 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods and uses |
| CA2763671A1 (en) * | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
| CN101432303A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗cdh3抗体的效应物功能来损伤细胞的方法 |
| WO2008146854A1 (ja) | 2007-05-28 | 2008-12-04 | National Institute Of Advanced Industrial Science And Technology | 抗モータリン抗体のパラトープ及びエピトープ |
| US8435749B2 (en) * | 2008-06-30 | 2013-05-07 | Oncotherapy Science, Inc. | Anti-CDH3 antibodies labeled with radioisotope label and uses thereof |
| AU2010242338B2 (en) * | 2009-05-01 | 2013-12-19 | Perseus Proteomics Inc. | Anti-cadherin antibody |
| US9017669B2 (en) | 2009-12-28 | 2015-04-28 | Oncotherapy Science, Inc. | Anti-CDH3 antibodies and uses thereof |
-
2011
- 2011-10-28 ES ES18182161T patent/ES2931477T3/es active Active
- 2011-10-28 HR HRP20181438TT patent/HRP20181438T1/hr unknown
- 2011-10-28 US US13/882,453 patent/US9328160B2/en active Active
- 2011-10-28 ES ES11836461.1T patent/ES2690469T3/es active Active
- 2011-10-28 EP EP18182161.2A patent/EP3404043B1/en active Active
- 2011-10-28 PL PL11836461T patent/PL2634194T3/pl unknown
- 2011-10-28 PT PT11836461T patent/PT2634194T/pt unknown
- 2011-10-28 JP JP2012540965A patent/JP6006640B2/ja active Active
- 2011-10-28 SI SI201131559T patent/SI2634194T1/sl unknown
- 2011-10-28 EP EP11836461.1A patent/EP2634194B1/en active Active
- 2011-10-28 HU HUE11836461A patent/HUE039375T2/hu unknown
- 2011-10-28 LT LTEP11836461.1T patent/LT2634194T/lt unknown
- 2011-10-28 WO PCT/JP2011/074958 patent/WO2012057328A1/ja not_active Ceased
- 2011-10-28 DK DK18182161.2T patent/DK3404043T3/da active
- 2011-10-28 EP EP20167547.7A patent/EP3708586A1/en active Pending
- 2011-10-28 PL PL18182161.2T patent/PL3404043T3/pl unknown
- 2011-10-28 RS RS20181024A patent/RS57646B1/sr unknown
- 2011-10-28 DK DK11836461.1T patent/DK2634194T3/en active
-
2016
- 2016-06-28 JP JP2016127379A patent/JP2016175945A/ja active Pending
-
2018
- 2018-09-17 CY CY181100957T patent/CY1121061T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2012057328A1 (ja) | 2014-05-12 |
| US9328160B2 (en) | 2016-05-03 |
| HRP20181438T1 (hr) | 2018-11-16 |
| JP6006640B2 (ja) | 2016-10-12 |
| EP2634194B1 (en) | 2018-08-15 |
| ES2690469T3 (es) | 2018-11-21 |
| HUE039375T2 (hu) | 2018-12-28 |
| EP2634194A4 (en) | 2014-05-28 |
| CY1121061T1 (el) | 2019-12-11 |
| RS57646B1 (sr) | 2018-11-30 |
| JP2016175945A (ja) | 2016-10-06 |
| PL2634194T3 (pl) | 2018-12-31 |
| DK2634194T3 (en) | 2018-10-01 |
| WO2012057328A1 (ja) | 2012-05-03 |
| EP3404043A1 (en) | 2018-11-21 |
| ES2931477T3 (es) | 2022-12-29 |
| EP3404043B1 (en) | 2022-10-26 |
| PT2634194T (pt) | 2018-10-19 |
| US20130317201A1 (en) | 2013-11-28 |
| EP2634194A1 (en) | 2013-09-04 |
| EP2634194A9 (en) | 2014-04-02 |
| LT2634194T (lt) | 2018-10-25 |
| DK3404043T3 (da) | 2022-11-14 |
| SI2634194T1 (sl) | 2018-11-30 |
| EP3708586A1 (en) | 2020-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2634194T (lt) | Anti-cdh3 antikūnas su dideliu gebėjimu internalizuotis | |
| HUS1900020I1 (hu) | CGRP ellenanyagok | |
| PL2581113T3 (pl) | Przeciwciało anty-tim-3 | |
| HRP20180952T1 (hr) | Anti-dll3 antitijelo | |
| PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| PL2575879T3 (pl) | Nowe przeciwciało anty-cMET | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| ZA201302459B (en) | Antibodies | |
| PL2625198T3 (pl) | Przeciwciała rozpoznające fosfo-tau | |
| ZA201208541B (en) | Antibody preparations | |
| GB201020738D0 (en) | Antibodies | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| EP2588141A4 (en) | ANTIBODY FORMULATIONS | |
| ZA201206055B (en) | Antibodies against cxcr4 | |
| GB201007957D0 (en) | Antibody | |
| GB201017780D0 (en) | Antibody | |
| GB201020751D0 (en) | Antibodies | |
| GB201005062D0 (en) | Antibodies |